In Reply We appreciate this clarification being made for JAMA Psychiatry readers from Williams. When our study1 commenced in 2010, tramadol had scientific promise as an opioid treatment medication because it was unscheduled, and human laboratory and small-scale clinical trials indicated it adequately suppressed opioid withdrawal. The reclassification of tramadol to Schedule IV in 2014 limited its potential as an opioid treatment and made its use for this indication more challenging. Williams is correct that Title 21 CRF §1306.072 stipulates a health care professional seeking to dispense narcotics for opioid maintenance or detoxification must be registered as part of a narcotic treatment program (section A) and must use medications approved by the US Food and Drug Administration for these indications (section D).
Dunn KE, Tompkins DA, Strain EC. Tramadol Extended-Release and Opioid Withdrawal Management—Legal Implications—Reply. JAMA Psychiatry. 2018;75(2):215. doi:10.1001/jamapsychiatry.2017.3827
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: